Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CytoDyn Inc.CYDY · Entity 5856 | Director | October 18, 2021 | October 20, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CytoDyn Inc.
Report date October 18, 2021 · Filed October 20, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.39 · Expires 2031-10-18 | Direct | 225,000 |
Reported balance
After 2021-10-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-10-18 · Grant · Acquired 225,000 · Balance 225,000 F1: The options will vest in 12 equal monthly installments beginning on July 1, 2021, subject to Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended) through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options will vest in 12 equal monthly installments beginning on July 1, 2021, subject to Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended) through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 15, 2018 Filed Feb 16, 2018 23:03 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Options (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0000899243-18-004436 · doc4.xml · derivative · entry 2 Naydenov Jordan G · CIK 0001469618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2023-06-01 Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 23:03 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerStock Options (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0000899243-18-004436 · doc4.xml · derivative · entry 1 Naydenov Jordan G · CIK 0001469618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2018-06-01 F1 · derivative.exercise_date: Such options were fully vested and exercisable as of the date of the reported transactions. Read SEC document |
| February 07, 2018 Filed Feb 10, 2018 01:04 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Options (right to buy) · Derivative | 96,397 | Not disclosed Strike: $0.56 | Not disclosed |
DisclosureSEC source: 0000899243-18-003457 · doc4.xml · derivative · entry 1 Naydenov Jordan G · CIK 0001469618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,397 Underlying: Common Stock · 96,397 shares Expires 2028-02-07 F1 · price: On February 7, 2018, the board of directors of CytoDyn Inc. approved an amendment to its director compensation program, providing for payment in stock options, in lieu of cash, of all unpaid director retainer fees for the four-quarter period ending February 28, 2018. The number of options awarded to each director was determined by applying a price of $0.31 per option, which was the fair value estimate of the option award as of the grant date, using the Black-Scholes option pricing model. Read SEC document |
| January 31, 2018 Filed Feb 3, 2018 01:19 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantWarrants (right to buy) · Derivative | 133,334 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0000899243-18-002768 · doc4.xml · derivative · entry 2 Naydenov Jordan G · CIK 0001469618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,334 Underlying: Common Stock · 133,334 shares Expires 2023-01-31 F1 · price: The reported securities were purchased together, as part of a registered direct offering, at a combined price of $0.50 per share of common stock and related warrants. Read SEC document |
| January 31, 2018 Filed Feb 3, 2018 01:19 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 207,248 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-002768 · doc4.xml · nonDerivative · entry 1 Naydenov Jordan G · CIK 0001469618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,304,490 F1 · price: The reported securities were purchased together, as part of a registered direct offering, at a combined price of $0.50 per share of common stock and related warrants. Read SEC document |
| January 31, 2018 Filed Sep 7, 2018 22:22 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantWarrants (right to buy) · Derivative | 66,666 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0000899243-18-024028 · doc4.xml · derivative · entry 2 Naydenov Jordan G · CIK 0001469618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,666 Underlying: Common Stock · 66,666 shares Expires 2022-07-26 F1 · price: The two transactions reported in Table II above involved the amendment of an outstanding warrant to reduce the exercise price from $1 per share to $0.75 per share. The amendment is reported above as the cancellation of the "old" warrant and the acquisition of a new one. Read SEC document |
| January 31, 2018 Filed Sep 7, 2018 22:22 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerWarrants (right to buy) · Derivative | 66,666 | Not disclosed Strike: $1.00 | Not disclosed |
DisclosureSEC source: 0000899243-18-024028 · doc4.xml · derivative · entry 1 Naydenov Jordan G · CIK 0001469618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 66,666 shares Expires 2022-07-26 F1 · price: The two transactions reported in Table II above involved the amendment of an outstanding warrant to reduce the exercise price from $1 per share to $0.75 per share. The amendment is reported above as the cancellation of the "old" warrant and the acquisition of a new one. Read SEC document |
| July 26, 2017 Filed Jul 28, 2017 20:07 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantWarrants · Derivative | 66,666 | Not disclosed Strike: $1.00 | Not disclosed |
DisclosureSEC source: 0000899243-17-019283 · doc4.xml · derivative · entry 2 Naydenov Jordan G · CIK 0001469618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,666 Underlying: Common Stock · 66,666 shares Expires 2022-07-26 F1 · derivative.exercise_price: Subject to adjustment in the event of certain stock split or reverse stock split recapitalizations. F3 · price: As part of a private offering to accredited investors, the reporting person purchased from the issuer for a combined price of $100 thousand (i) a $100 thousand convertible promissory note, bearing interest at 7.0% annually, which is convertible into shares of the issuer's common stock at an initial conversion price of $0.75 per share, and (ii) a warrant covering 50% of the number of shares underlying the convertible promissory note, at an exercise price of $1.00 per share. Read SEC document |
| July 26, 2017 Filed Jul 28, 2017 20:07 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantConvertible Promissory Note · Derivative | 100,000 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0000899243-17-019283 · doc4.xml · derivative · entry 1 Naydenov Jordan G · CIK 0001469618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 133,333 shares Expires 2018-01-31 F1 · derivative.exercise_price: Subject to adjustment in the event of certain stock split or reverse stock split recapitalizations. F3 · price: As part of a private offering to accredited investors, the reporting person purchased from the issuer for a combined price of $100 thousand (i) a $100 thousand convertible promissory note, bearing interest at 7.0% annually, which is convertible into shares of the issuer's common stock at an initial conversion price of $0.75 per share, and (ii) a warrant covering 50% of the number of shares underlying the convertible promissory note, at an exercise price of $1.00 per share. F2 · derivative.underlying_shares: Does not include additional shares issuable upon conversion of accrued interest. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 20:46 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Options (right to buy) · Derivative | 75,000 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0000899243-17-015354 · doc4.xml · derivative · entry 1 Naydenov Jordan G · CIK 0001469618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2027-06-01 F1 · derivative.exercise_date: Subject to stockholder approval, at the next annual meeting, of the increase in the number of shares of common stock authorized for issuance under the CytoDyn Inc. 2012 Equity Incentive Plan, as amended, the options will vest in four equal quarterly installments commencing on September 1, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.